Tocagen Aims Double Barrels At Glioma
Executive Summary
Emerging Company Profile: Gene therapy technology company Tocagen has glioma in its sights. Marty Duvall, newly appointed CEO of the San Diego-based firm, tells Mike Ward how his company’s approach has potential to double survival in one of the deadliest diseases, for which little to no effective treatments exist.
You may also be interested in...
Tocagen On The Rocks With Phase III Brain Cancer Study Failure
The firm’s stock crashed on news that its Toca 511/Toca FC regimen did not show an overall survival benefit or meet any secondary endpoints in a Phase III study in recurrent high-grade glioma.
After Tocagen Thaws IPO Freeze, Verona And Zymeworks Bring April Total To Three
With three biopharma initial public offerings in April, the second quarter is on track to beat the first quarter's total of five IPOs – three in January and two in March – and several more are in the queue.
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.